Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
about
Citalopram versus other anti-depressive agents for depressionRight patient, right treatment, right time: biosignatures and precision medicine in depression.Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.A comprehensive systematic review and meta-analysis of pharmacological and dietary supplement interventions in paediatric autism: moderators of treatment response and recommendations for future research.Diagnostic classification of unipolar depression based on resting-state functional connectivity MRI: effects of generalization to a diverse sample.Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response.Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants.A simple attention test in the acute phase of a major depressive episode is predictive of later functional remission.Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study.Brain-Based Biomarkers for the Treatment of Depression: Evolution of an Idea.Harmonization of cortical thickness measurements across scanners and sites.Exercise is an effective treatment for positive valence symptoms in major depression.Relations between cortical thickness, serotonin 1A receptor binding, and structural connectivity: A multimodal imaging study.Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination.Cortical thickness is not associated with current depression in a clinical treatment study.A comparison of structural connectivity in anxious depression versus non-anxious depression.Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study.Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study.Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial.Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC StudyPretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorderCan an Integrated Science Approach to Precision Medicine Research Improve Lithium Treatment in Bipolar Disorders?
P2860
Q24202141-951B87CC-66C5-4C29-9442-604D97277663Q37274677-704D496C-EA54-42CC-A330-59424BBEA579Q38636012-24C14AAE-DAA6-46A8-B4A9-5278858017CDQ38657429-8A38B343-05D4-45BA-A0EE-7A71DDC7AD7EQ38770053-BB314667-09D8-43D5-B262-91C75B1311AFQ38775840-347257E4-D3C3-485D-99CB-63CBB4A7759EQ38779919-2F548275-C94E-4475-A790-57C9F106B6D6Q38939633-C2EE567F-87DF-4144-A78D-D221DC85BC1FQ39177113-BF444DF2-98E3-4C4E-9ED9-DA1DC1B6B79BQ39298913-6C70C924-EF2D-4982-A059-72C7A5753EBAQ47145212-50BC7247-23BC-4917-BC02-CAC97418432FQ47281697-7A20D81A-0EF9-4A1D-9403-751BB15AEC69Q47332512-3D580441-B662-4DB0-9D16-F690DBB55610Q47364349-C0F49E96-1E4A-49B5-BBA3-4CE2BDC690BFQ47565260-920846D5-76A2-47F7-9F29-01507AAB648FQ47666907-9CFB114F-EE46-42A6-92E0-17F612ECCA4FQ47744143-A5916B33-A856-4058-A449-68F71B0212E6Q47862996-90DC9AF2-B7D2-4179-896F-1EBCB5C4FEDFQ47977947-7CFECA52-E23C-4C9E-B3B9-E3530C79C8D1Q52089873-B78594A9-EBC6-4359-9D59-828F14185109Q52566660-6377A021-4EBE-425C-BA09-555CB6AAA999Q52594008-A40A5C33-5E43-4D2F-BCC8-F6EF52BD99EBQ57335253-381F25D7-DFBD-4AD9-803F-4D9E9ACFEBCAQ57828974-93DEDAB1-D199-4084-8FF9-8D097954ECDAQ58729511-6EBE1169-457C-4BDB-86D0-4185B8A6F839
P2860
Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Establishing moderators and bi ...... EMBARC): Rationale and design.
@en
type
label
Establishing moderators and bi ...... EMBARC): Rationale and design.
@en
prefLabel
Establishing moderators and bi ...... EMBARC): Rationale and design.
@en
P2093
P2860
P50
P1476
Establishing moderators and bi ...... EMBARC): Rationale and design.
@en
P2093
Benji T Kurian
Bruce D Grannemann
Crystal Cooper
David W Morris
Diego Pizzagalli
Eva Petkova
Gerard Bruder
Madhukar H Trivedi
Marisa Toups
Mary L Phillips
P2860
P356
10.1016/J.JPSYCHIRES.2016.03.001
P577
2016-03-15T00:00:00Z